- Home
- ELS vs EXEL Comparison
ELS vs EXEL Comparison
Compare ELS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELS
- EXEL
- Stock Information
- Founded
- ELS 1992
- EXEL 1994
- Country
- ELS United States
- EXEL United States
- Employees
- ELS N/A
- EXEL N/A
- Industry
- ELS Real Estate Investment Trusts
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELS Real Estate
- EXEL Health Care
- Exchange
- ELS Nasdaq
- EXEL Nasdaq
- Market Cap
- ELS 11.9B
- EXEL 11.3B
- IPO Year
- ELS 1993
- EXEL 2000
- Fundamental
- Price
- ELS $61.51
- EXEL $44.86
- Analyst Decision
- ELS Buy
- EXEL Buy
- Analyst Count
- ELS 10
- EXEL 18
- Target Price
- ELS $73.90
- EXEL $43.65
- AVG Volume (30 Days)
- ELS 1.3M
- EXEL 3.7M
- Earning Date
- ELS 07-21-2025
- EXEL 08-05-2025
- Dividend Yield
- ELS 3.35%
- EXEL N/A
- EPS Growth
- ELS 5.86
- EXEL 237.58
- EPS
- ELS 1.94
- EXEL 2.20
- Revenue
- ELS $1,537,798,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- ELS $1.67
- EXEL $9.37
- Revenue Next Year
- ELS $3.92
- EXEL $11.05
- P/E Ratio
- ELS $31.67
- EXEL $20.33
- Revenue Growth
- ELS 1.94
- EXEL 24.49
- 52 Week Low
- ELS $58.86
- EXEL $22.13
- 52 Week High
- ELS $76.60
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- ELS 42.06
- EXEL 56.79
- Support Level
- ELS $61.47
- EXEL $43.21
- Resistance Level
- ELS $62.59
- EXEL $48.74
- Average True Range (ATR)
- ELS 1.07
- EXEL 2.01
- MACD
- ELS -0.01
- EXEL 0.05
- Stochastic Oscillator
- ELS 26.27
- EXEL 31.61
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.